Incyte to Host Conference Call Today to Discuss Collaborative Research and License Agreement with Pfizer for the Development and Commercialization of CCR2 Antagonists; Conference Call is Scheduled to Begin at 8:30 a.m. ET Today

Business Wire, Nov 21, 2005

WILMINGTON, Del. -- Incyte Corporation (Nasdaq:INCY) announced that it will host a conference call at 8:30 am ET today to discuss its collaborative research and license agreement with Pfizer for the development and commercialization of CCR2 antagonists. A copy of the press release, also released today, can be accessed at www.incyte.com.

The schedule and dial in information for the conference call are as follows:

--  Conference Call:               November 21, 2005 at 8:30 a.m. ET

  --  Domestic Dial In Number:       877-692-2592

  --  International Dial In Number:  973-582-2700

  --  Conference ID #                6747516

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial in number for the U.S. is 877-519-4471 and for international callers is 973-341-3080. The replay pin number is 6747516.

The conference call will also be webcast live on CCBN and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts.